| Dr Jula Veerapong, MD | |
|
3855 Health Sciences Dr, La Jolla, CA 92093-3218 | |
| (858) 822-6173 | |
| (858) 228-5153 |
| Full Name | Dr Jula Veerapong |
|---|---|
| Gender | Male |
| Speciality | General Surgery |
| Experience | 22 Years |
| Location | 3855 Health Sciences Dr, La Jolla, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1801039490 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Uc San Diego Health Hillcrest - Hillcrest Med Ctr | San diego, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Regents Of The University Of California | 3577476761 | 1692 |
News Archive
A national team of researchers has developed a first-of-its-kind, 3D-printed guide that helps regrow both the sensory and motor functions of complex nerves after injury. The groundbreaking research has the potential to help more than 200,000 people annually who experience nerve injuries or disease.
St. Jude Children's Research Hospital has been listed among the top 10 "Best Places to Work in Academia" by The Scientist magazine - this year's seventh place ranking is the fourth straight year the institution has placed in the top 10.
A novel comprehensive plan for the regulation of tobacco and nicotine was announced by the Food and Drug Administration (FDA), USA, on 28th July 2017. This plan is expected to serve as a roadmap that can be implemented through multiple years in improving the protection of kids as well as reducing the diseases and deaths related to tobacco.
Neoprobe Corporation, a diversified developer of innovative oncology surgical and diagnostic products, announced today that it completed the previously announced sale of its neoprobe GDS line of gamma detection device systems to Devicor Medical Products, Inc. for $30 million in upfront consideration, plus up to an additional $20 million in royalties based on Devicor's achievement of certain revenue milestones.
CALGB 80405, a large, independent, phase III study, designed to assess the superiority in overall survival (OS) of cetuximab over Avastin (bevacizumab) when combined with either FOLFOX or FOLFIRI chemotherapy in people with previously untreated, KRAS wild-type advanced (metastatic) bowel cancer has failed to meet this primary endpoint.
› Verified 2 days ago
| Entity Name | Regents Of The University Of California |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740382993 PECOS PAC ID: 3577476761 Enrollment ID: O20040430001354 |
News Archive
A national team of researchers has developed a first-of-its-kind, 3D-printed guide that helps regrow both the sensory and motor functions of complex nerves after injury. The groundbreaking research has the potential to help more than 200,000 people annually who experience nerve injuries or disease.
St. Jude Children's Research Hospital has been listed among the top 10 "Best Places to Work in Academia" by The Scientist magazine - this year's seventh place ranking is the fourth straight year the institution has placed in the top 10.
A novel comprehensive plan for the regulation of tobacco and nicotine was announced by the Food and Drug Administration (FDA), USA, on 28th July 2017. This plan is expected to serve as a roadmap that can be implemented through multiple years in improving the protection of kids as well as reducing the diseases and deaths related to tobacco.
Neoprobe Corporation, a diversified developer of innovative oncology surgical and diagnostic products, announced today that it completed the previously announced sale of its neoprobe GDS line of gamma detection device systems to Devicor Medical Products, Inc. for $30 million in upfront consideration, plus up to an additional $20 million in royalties based on Devicor's achievement of certain revenue milestones.
CALGB 80405, a large, independent, phase III study, designed to assess the superiority in overall survival (OS) of cetuximab over Avastin (bevacizumab) when combined with either FOLFOX or FOLFIRI chemotherapy in people with previously untreated, KRAS wild-type advanced (metastatic) bowel cancer has failed to meet this primary endpoint.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jula Veerapong, MD Po Box 232410, San Diego, CA 92193-2410 Ph: (858) 249-6749 | Dr Jula Veerapong, MD 3855 Health Sciences Dr, La Jolla, CA 92093-3218 Ph: (858) 822-6173 |
News Archive
A national team of researchers has developed a first-of-its-kind, 3D-printed guide that helps regrow both the sensory and motor functions of complex nerves after injury. The groundbreaking research has the potential to help more than 200,000 people annually who experience nerve injuries or disease.
St. Jude Children's Research Hospital has been listed among the top 10 "Best Places to Work in Academia" by The Scientist magazine - this year's seventh place ranking is the fourth straight year the institution has placed in the top 10.
A novel comprehensive plan for the regulation of tobacco and nicotine was announced by the Food and Drug Administration (FDA), USA, on 28th July 2017. This plan is expected to serve as a roadmap that can be implemented through multiple years in improving the protection of kids as well as reducing the diseases and deaths related to tobacco.
Neoprobe Corporation, a diversified developer of innovative oncology surgical and diagnostic products, announced today that it completed the previously announced sale of its neoprobe GDS line of gamma detection device systems to Devicor Medical Products, Inc. for $30 million in upfront consideration, plus up to an additional $20 million in royalties based on Devicor's achievement of certain revenue milestones.
CALGB 80405, a large, independent, phase III study, designed to assess the superiority in overall survival (OS) of cetuximab over Avastin (bevacizumab) when combined with either FOLFOX or FOLFIRI chemotherapy in people with previously untreated, KRAS wild-type advanced (metastatic) bowel cancer has failed to meet this primary endpoint.
› Verified 2 days ago
Dr. Howard Takiff, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 760 La Canada St, La Jolla, CA 92037 Phone: 949-981-4018 | |
Mahmoud Malas, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 9434 Medical Center Dr Fl 1, La Jolla, CA 92037 Phone: 619-543-6980 Fax: 858-657-5033 | |
Cheryl Lorraine Olson, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 9850 Genesee Ave, Suite 660, La Jolla, CA 92037 Phone: 858-452-5054 Fax: 858-452-5097 | |
James G. Schwendig, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 9888 Genesee Ave, Lj-601, La Jolla, CA 92037 Phone: 858-626-6350 Fax: 858-626-6354 | |
Angeles Baquerizo, Surgery Medicare: Accepting Medicare Assignments Practice Location: 10666 N Torrey Pines Rd # 200n, La Jolla, CA 92037 Phone: 858-544-4310 | |
Dr. David Alexander Frankel, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 10666 N Torrey Pines Rd, La Jolla, CA 92037 Phone: 858-554-8988 | |
Ayemoethu Ma, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 10666 N Torrey Pines Rd # Ms 213, La Jolla, CA 92037 Phone: 858-554-8984 Fax: 858-554-5055 |